20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker
Main Author: | |
---|---|
Publication Date: | 2024 |
Other Authors: | , , , |
Format: | Article |
Language: | eng |
Source: | Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
Download full: | https://doi.org/10.32932/gecp.2022.02.018 |
Summary: | Introduction: Malignant pleural mesothelioma (MPM) is a rare, but aggressive incurable cancer. A variety of prognostic tools have been developed to guide clinicians and patients in the management of MPM regarding the most appropriate therapy and survival time. Objectives: To evaluate the usefulness of the Brims’ decision tree analysis, the EORTC prognostic score, the CALGB prognostic groups, the modified Glasgow Prognostic Score (mGPS), and the LENT prognostic score in our MPM patients. Methods: Local retrospective database analysis of patients with MPM diagnosed between 2000 and 2020. The different prognostic scores were applied and MPM group risks’ evolution was analyzed. Statistical analysis was performed with IBM® SPSS® Statistics 25. Results: A total of 67 patients were evaluated (55 males, 82.1%). Epithelioid MPM was the commonest histological type (51 patients, 76.1%). Median overall survival (OS) was 11 months (IQR 23) and median progression free-survival (PFS) was 7 months (IQR 12.5). Survival distributions were statistically significantly different for the Brims’ and the mGPS’ groups (respectively, χ2 = 7.188, p = .027, and χ2 = 6.46, p = .04). For EORTC, CALGB and LENT score, there were not statistically significant differences in survival distributions (respectively, χ2 =.57, p = .811; χ2 = 7.978, p = .157; and χ2 = 1.23, p = .267). Brims’ model and mGPS statistically significantly predicted OS (respectively, F(1,57) = 11.1, p < 0.01, and F(1,32) = 6.846, p = .01). EORTC, CALGB and LENT failed to statistically significantly predict OS (respectively, F(1,44) = .003, p = .955; F(1.43) = .722, p = 0.4; and F(1,14) = 1.193, p = .293). Conclusion: The small number of patients included and missing data for some parameters are limitations of our analysis. However, to our knowledge, this was the first study and the largest cohort to address MPM prognostic scores in our country. In our cohort, the Brims’ model and mGPS were useful in predicting survival. Both are simple tools with easily accessible parameters and should be considered for clinical practice. |
id |
RCAP_d959c53c2f87859d36e2ad2dea6002f8 |
---|---|
oai_identifier_str |
oai:ojs.thoracjournal.com:article/44 |
network_acronym_str |
RCAP |
network_name_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository_id_str |
https://opendoar.ac.uk/repository/7160 |
spelling |
20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker20 anos de abordagem do mesotelioma pleural maligno: uma revisão da nossa experiência e a a procura pelo marcador prognóstico idealMesotheliomamalignantsurvival analysisprognosisMesotelioma pleural malignosobrevidaprognósticoIntroduction: Malignant pleural mesothelioma (MPM) is a rare, but aggressive incurable cancer. A variety of prognostic tools have been developed to guide clinicians and patients in the management of MPM regarding the most appropriate therapy and survival time. Objectives: To evaluate the usefulness of the Brims’ decision tree analysis, the EORTC prognostic score, the CALGB prognostic groups, the modified Glasgow Prognostic Score (mGPS), and the LENT prognostic score in our MPM patients. Methods: Local retrospective database analysis of patients with MPM diagnosed between 2000 and 2020. The different prognostic scores were applied and MPM group risks’ evolution was analyzed. Statistical analysis was performed with IBM® SPSS® Statistics 25. Results: A total of 67 patients were evaluated (55 males, 82.1%). Epithelioid MPM was the commonest histological type (51 patients, 76.1%). Median overall survival (OS) was 11 months (IQR 23) and median progression free-survival (PFS) was 7 months (IQR 12.5). Survival distributions were statistically significantly different for the Brims’ and the mGPS’ groups (respectively, χ2 = 7.188, p = .027, and χ2 = 6.46, p = .04). For EORTC, CALGB and LENT score, there were not statistically significant differences in survival distributions (respectively, χ2 =.57, p = .811; χ2 = 7.978, p = .157; and χ2 = 1.23, p = .267). Brims’ model and mGPS statistically significantly predicted OS (respectively, F(1,57) = 11.1, p < 0.01, and F(1,32) = 6.846, p = .01). EORTC, CALGB and LENT failed to statistically significantly predict OS (respectively, F(1,44) = .003, p = .955; F(1.43) = .722, p = 0.4; and F(1,14) = 1.193, p = .293). Conclusion: The small number of patients included and missing data for some parameters are limitations of our analysis. However, to our knowledge, this was the first study and the largest cohort to address MPM prognostic scores in our country. In our cohort, the Brims’ model and mGPS were useful in predicting survival. Both are simple tools with easily accessible parameters and should be considered for clinical practice.Introdução: O mesotelioma pleural maligno (MPM) é um cancro raro, mas agressivo e sem cura. Têm sido desenvolvidas diversas ferramentas na tentativa de ajudar os clínicos e os doentes na abordagem do MPM, particularmente no que concerne à escolha da terapêutica apropriada e à sobrevida. Objetivos: Avaliar a utilidade da Brims’ decision tree, do EORTC prognostic score, do CALGB prognostic groups, do modified Glasgow Prognostic Score (mGPS), e do LENT prognostic score nos nossos doentes com MPM. Métodos: Foi conduzida uma análise retrospectiva de todos os doentes com MPM diagnosticados entre 2000 e 2020. Os diferentes scores de prognóstico foram aplicados, tendo-se avaliado a evolução da sobrevida em função dos diferentes grupos de risco para o MPM. Resultados: Foram avaliados um total de 67 doentes (55 homens, 82,1%). O MPM epitelióide foi o tipo histológico mais comum (51 doentes, 76,1%). A sobrevida global mediana (OS) foi de 11 meses (IQR 23) e a sobrevida livre de progressão mediana (PFS) foi de 7 meses (IQR 12,5). A sobrevida foi diferente de modo estatisticamente significativo entre os grupos do modelo de Brims e do mGPS (respetivamente, χ2 = 7.188, p = .027, and χ2 = 6.46, p = .04). Para os scores EORTC, CALGB e LENT, não existiram diferenças estatisticamente significativas na distribuição da sobrevida (respetivamente, χ2 =.57, p = .811; χ2 = 7.978, p = .157; e χ2 = 1.23, p = .267). O modelo de Brims e o mGPS previram a OS de modo estatisticamente significativo (respetivamente, F(1,57) = 11.1, p < 0.01, e F(1,32) = 6.846, p = .01). Os scores EORTC, CALGB e LENT não conseguiram prever de modo estatisticamente significativo a OS (respetivamente, F(1,44) = .003, p = .955; F(1.43) = .722, p = 0.4; e F(1,14) = 1.193, p = .293). Conclusão: O reduzido número de doentes e a inexistência de dados de alguns parâmetros são limitações da nossa análise. No entanto, do nosso conhecimento, este foi o primeiro estudo a abordar os diferentes scores de prognóstico do MPM no nosso país. Na nossa coorte, o modelo de Brims e o mGPS demonstraram-se úteis na previsão da sobrevida. Tratam-se de ferramentas simples, que incorporam parâmetros facilmente acessíveis, e que, por isso, sugere-se a sua consideração na a prática clínica.Grupo de Estudos de Cancro do Pulmão (GECP)2024-12-28info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.32932/gecp.2022.02.018https://doi.org/10.32932/gecp.2022.02.018Thoracic Cancer Journal; Vol. 18 No. 2 (2021); 9-17reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAPenghttps://thoracjournal.com/index.php/tcj/article/view/44https://thoracjournal.com/index.php/tcj/article/view/44/40Copyright (c) 2024 Author(s) (or their employer(s)) and THORAC 2024info:eu-repo/semantics/openAccessNunes Caldeira, JoãoRodrigues Sousa, SofiaFigueiredo, Ana MariaPêgo, AliceBarata, Fernando2025-01-22T08:57:30Zoai:ojs.thoracjournal.com:article/44Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T19:40:59.900431Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse |
dc.title.none.fl_str_mv |
20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker 20 anos de abordagem do mesotelioma pleural maligno: uma revisão da nossa experiência e a a procura pelo marcador prognóstico ideal |
title |
20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker |
spellingShingle |
20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker Nunes Caldeira, João Mesothelioma malignant survival analysis prognosis Mesotelioma pleural maligno sobrevida prognóstico |
title_short |
20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker |
title_full |
20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker |
title_fullStr |
20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker |
title_full_unstemmed |
20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker |
title_sort |
20 years managing malignant pleural mesothelioma: a review of our experience and the quest for the optimal prognostic marker |
author |
Nunes Caldeira, João |
author_facet |
Nunes Caldeira, João Rodrigues Sousa, Sofia Figueiredo, Ana Maria Pêgo, Alice Barata, Fernando |
author_role |
author |
author2 |
Rodrigues Sousa, Sofia Figueiredo, Ana Maria Pêgo, Alice Barata, Fernando |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Nunes Caldeira, João Rodrigues Sousa, Sofia Figueiredo, Ana Maria Pêgo, Alice Barata, Fernando |
dc.subject.por.fl_str_mv |
Mesothelioma malignant survival analysis prognosis Mesotelioma pleural maligno sobrevida prognóstico |
topic |
Mesothelioma malignant survival analysis prognosis Mesotelioma pleural maligno sobrevida prognóstico |
description |
Introduction: Malignant pleural mesothelioma (MPM) is a rare, but aggressive incurable cancer. A variety of prognostic tools have been developed to guide clinicians and patients in the management of MPM regarding the most appropriate therapy and survival time. Objectives: To evaluate the usefulness of the Brims’ decision tree analysis, the EORTC prognostic score, the CALGB prognostic groups, the modified Glasgow Prognostic Score (mGPS), and the LENT prognostic score in our MPM patients. Methods: Local retrospective database analysis of patients with MPM diagnosed between 2000 and 2020. The different prognostic scores were applied and MPM group risks’ evolution was analyzed. Statistical analysis was performed with IBM® SPSS® Statistics 25. Results: A total of 67 patients were evaluated (55 males, 82.1%). Epithelioid MPM was the commonest histological type (51 patients, 76.1%). Median overall survival (OS) was 11 months (IQR 23) and median progression free-survival (PFS) was 7 months (IQR 12.5). Survival distributions were statistically significantly different for the Brims’ and the mGPS’ groups (respectively, χ2 = 7.188, p = .027, and χ2 = 6.46, p = .04). For EORTC, CALGB and LENT score, there were not statistically significant differences in survival distributions (respectively, χ2 =.57, p = .811; χ2 = 7.978, p = .157; and χ2 = 1.23, p = .267). Brims’ model and mGPS statistically significantly predicted OS (respectively, F(1,57) = 11.1, p < 0.01, and F(1,32) = 6.846, p = .01). EORTC, CALGB and LENT failed to statistically significantly predict OS (respectively, F(1,44) = .003, p = .955; F(1.43) = .722, p = 0.4; and F(1,14) = 1.193, p = .293). Conclusion: The small number of patients included and missing data for some parameters are limitations of our analysis. However, to our knowledge, this was the first study and the largest cohort to address MPM prognostic scores in our country. In our cohort, the Brims’ model and mGPS were useful in predicting survival. Both are simple tools with easily accessible parameters and should be considered for clinical practice. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-12-28 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.32932/gecp.2022.02.018 https://doi.org/10.32932/gecp.2022.02.018 |
url |
https://doi.org/10.32932/gecp.2022.02.018 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://thoracjournal.com/index.php/tcj/article/view/44 https://thoracjournal.com/index.php/tcj/article/view/44/40 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2024 Author(s) (or their employer(s)) and THORAC 2024 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2024 Author(s) (or their employer(s)) and THORAC 2024 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Grupo de Estudos de Cancro do Pulmão (GECP) |
publisher.none.fl_str_mv |
Grupo de Estudos de Cancro do Pulmão (GECP) |
dc.source.none.fl_str_mv |
Thoracic Cancer Journal; Vol. 18 No. 2 (2021); 9-17 reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia instacron:RCAAP |
instname_str |
FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
collection |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) |
repository.name.fl_str_mv |
Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia |
repository.mail.fl_str_mv |
info@rcaap.pt |
_version_ |
1833598257587027968 |